Compare Abeona Therapeutics Inc (ABEO) vs RLX Technology Inc (RLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs RLX Technology Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while RLX Technology Inc trades at $1.98 (market cap $2.32B). The key difference: RLX Technology Inc is far larger — about 6.2× Abeona Therapeutics Inc's market cap, and RLX Technology Inc pays a 5.26% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | RLX | |
|---|---|---|
Market Cap | $373.32M | $2.32B |
Sector | Health | Technology |
52-Week High | $7.23 | $2.73 |
52-Week Low | $4.17 | $1.79 |
Enterprise Value | $228.22M | $955.96M |
Dividend Yield | — | 5.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
RLX stock trades at $1.96, up 1.55% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported strong 2025 results with $3.62B revenue and $922M net income, though recent quarters have missed EPS expectations. Positive news highlights international expansion and a cash-rich, debt-free balance sheet, with JPMorgan increasing its stake significantly in Q3 2025.
Outlook is cautiously optimistic given solid profitability and industry growth potential, but risks include regulatory scrutiny in the vaping sector and consistent earnings misses. The sole analyst coverage recommends Hold, reflecting balanced risk-reward amid high cash flows but uncertain near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
